Over-expression of GUSB leads to primary resistance of anti-PD1 therapy in hepatocellular carcinoma

Treatment with immunotherapy, particularly immune checkpoint blockade, can lead to benefit in the clinical setting. However, many preclinical and clinical studies suggest that resistance to anti-PD1 treatment frequently occurs, resulting in tumor relapse and treatment failure in cancer including hepatocellular carcinoma (HCC) patients. In this study ,10 HCC patients were treated with anti-PD1, and the biopsy samples before treatment were used for 289 nanostring panel RNA sequencing to compare responding and non-responding tumors to find possible pretreatment biomarkers or targets of the anti-PD1 therapy response In this study ,10 HCC patients were treated with anti-PD1 therapy. To found possible pretreatment biomarkers or targets of anti-PD1 treatment response, pre-treated biopsy samples of these patients were used for 289 nanostring panel RNA sequencing to compare responding and non-responding tumors